Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):774-776. doi: 10.1016/j.clml.2020.08.017. Epub 2020 Aug 22.

Authors

Hajime Yasuda¹, Yutaka Tsukune², Naoki Watanabe², Kazuya Sugimoto², Ayana Uchimura², Misa Tateyama³, Yosuke Miyashita³, Yusuke Ochi³, Norio Komatsu²

Affiliations

¹ Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. Electronic address: hyasuda@juntendo.ac.jp.
² Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
³ Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.

No abstract available

Keywords: Atypical presentation; CHOP; Coronavirus; Hematological malignancy; Obinutuzumab.

Publication types

Case Reports

MeSH terms

Antibodies, Neutralizing / blood*
Antibodies, Neutralizing / immunology
Antibodies, Viral / blood*
Antibodies, Viral / immunology
Antineoplastic Agents, Immunological / adverse effects*
Betacoronavirus / immunology*
Betacoronavirus / isolation & purification
COVID-19
Chronic Disease
Coronavirus Infections / blood
Coronavirus Infections / complications
Coronavirus Infections / diagnosis
Coronavirus Infections / immunology*
Female
Humans
Lung / diagnostic imaging
Lymphoma, Follicular / complications
Lymphoma, Follicular / drug therapy
Lymphoma, Follicular / immunology
Middle Aged
Pandemics
Pneumonia, Viral / blood
Pneumonia, Viral / complications
Pneumonia, Viral / diagnosis
Pneumonia, Viral / immunology*
Rituximab / adverse effects*
SARS-CoV-2
Tomography, X-Ray Computed

Substances

Antibodies, Neutralizing
Antibodies, Viral
Antineoplastic Agents, Immunological
Rituximab